These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 30009497)

  • 1. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
    Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
    J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
    Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
    J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
    Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
    Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
    Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
    Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
    Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
    Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
    Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
    Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
    Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
    Zhang L; Chen Y; Wang K
    Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
    Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
    Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.
    Anton C; Carvalho FM; Oliveira EI; Maciel GA; Baracat EC; Carvalho JP
    Clinics (Sao Paulo); 2012; 67(5):437-41. PubMed ID: 22666786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z; Tao X; Ying C
    Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of HE4 and ROMA among Chinese women.
    Shen Y; Zhao L; Lu S
    Clin Chim Acta; 2020 Jan; 500():42-46. PubMed ID: 31626761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors.
    Janas L; Stachowiak G; Glowacka E; Piwowarczyk I; Kajdos M; Soja M; Masternak M; Nowak M
    Ginekol Pol; 2024; 95(5):321-327. PubMed ID: 36597746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.